Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity

Mack N. Barnes, Jessy S. Deshane, Gene P. Siegal, Ronald D. Alvarez, David T. Curiel

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

erbB-2 is a cell surface transmembrane glycoprotein which, when overexpressed, has been shown to be relevant to intrinsic tumor cell chemoresistance. Thus, strategies to down-regulate cell surface erbB-2 have resulted in enhanced tumor cell chemosensitivity. We have recently reported a gene therapy strategy to down-modulate erbB-2 expression using a plasmid construct encoding an intracellular single chain antibody. Therefore, we now demonstrate enhanced chemosensitivity to cis-diamminedichloroplatinum in erbB-2 overexpressing tumor cells and a model system of stable clones using an intracellular single chain antibody. These findings are consistent with the hypothesis that erbB-2 plays a role in tumor cell chemoresistance. In addition, these findings represent a novel gene therapy approach to overcome erbB-2 mediated tumor cell chemoresistance.

Original languageEnglish
Pages (from-to)1089-1095
Number of pages7
JournalClinical Cancer Research
Volume2
Issue number7
StatePublished - Jul 1 1996
Externally publishedYes

Fingerprint Dive into the research topics of 'Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity'. Together they form a unique fingerprint.

  • Cite this